Munich-based XO Life bags €7M to help the pharma industry better understand patients

Munich-based XO Life, a digital health startup, announced on Thursday, August 22, that it has secured €7M in funding led by Sandwater and Grazia Equity. 

Additionally, Vi Partners and Bayern Kapital co-led the round, with participation from existing investors, including aescuvest, Isartal Ventures, Winning Mindset, MediVentures GmbH, capacura, and many more.

The fund will allow XO Life to accelerate its growth and international expansion plans for its ImpactMonitor platform, a unique meta-platform set to redefine digital patient support.

Dr. Friderike Bruchmann, CEO of XO Life says, 
“This investment will enable us to advance our technology and expand internationally. Having proven our success in the German market, we are eager to address global health challenges and bring our innovative solutions to a wider audience.”

XO Life: Access to reliable health information

In an age where patients often rely on platforms like Google and Facebook for health information, a trustworthy, all-encompassing alternative is critical. 

Here’s where XO Life comes into play!

Led by Dr. Friderike Bruchmann, XO Life has created a globally unique meta-platform, the ImpactMonitor platform, for digital product and therapy support for patients. 

With this platform, patients are accompanied during their product use or therapy with verified medical and health-related content, record their health and therapy progress, receive personalised insights and medical support from experts, and can exchange information with other patients.

Manufacturers can license their products and therapy areas on the ImpactMonitor platform and make them available to their patients with their branding, content, questions, and services. 

By providing personalised information and continuous support during therapy, manufacturers make an important contribution to therapy success, therapy compliance, and patient application safety.

Currently, the German company works with global market leaders, German pharmaceutical medium-sized companies, and orphan drug manufacturers and is now offering the ImpactMonitor platform in all European countries and languages.

‍